title: Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention.
abstract: OBJECTIVE
  The benefits of antihypertensive (AH) drugs on the risks of major cardiovascular outcomes have been demonstrated in clinical trials. However, approximately half of hypertensive patients do not adhere well to their prescribed AH therapy in actual practice. The purpose of this study was to assess the impact of adherence to AH agents on the incidence of cerebrovascular disease (CD) in real-world practice.
  
  
  METHODS
  A cohort of 83 267 hypertensive patients was reconstructed from the Régie de l'assurance maladie du Québec databases. Subjects included were between 45 and 85 years old, initially free of cardiovascular disease, and newly treated for hypertension with AH agents between 1999 and 2004. A nested case-control design was conducted to study CD occurrence. Every case was matched for age and duration of follow-up with up to 15 randomly selected control subjects. The adherence to AH drugs was measured by calculating the medication possession ratio. Conditional logistic regression models were performed to assess the association between adherence to AH agents and CD adjusting for various potential confounders.
  
  
  RESULTS
  At cohort entry, the mean patient age was 65 years, 37.3% were male, 8.6% had diabetes, and 19.5% had dyslipidemia. High adherence (>/=80%) to AH drugs significantly decreased the risk of CD by 22% (rate ratio, 0.78; 95% CI, 0.70 to 0.87) compared with lower adherence. Male gender, occurrence of cardiovascular disease during follow-up, and dyslipidemia were risk factors for CD.
  
  
  CONCLUSIONS
  High adherence to AH therapy is associated with a reduced risk of CD outside the context of clinical trials in primary prevention.
authors.affiliation: Faculty of Pharmacy, PO Box 6128, Centre-Ville Station, Montréal, Québec, Canada.
authors.forename: Fatima-Zohra
authors.initials: FZ
authors.lastname: Kettani
authors.forename: Alice
authors.initials: A
authors.lastname: Dragomir
authors.forename: Robert
authors.initials: R
authors.lastname: Côté
authors.forename: Louise
authors.initials: L
authors.lastname: Roy
authors.forename: Anick
authors.initials: A
authors.lastname: Bérard
authors.forename: Lucie
authors.initials: L
authors.lastname: Blais
authors.forename: Lyne
authors.initials: L
authors.lastname: Lalonde
authors.forename: Pierre
authors.initials: P
authors.lastname: Moreau
authors.forename: Sylvie
authors.initials: S
authors.lastname: Perreault
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology; D016022:Case-Control Studies; D002561:Cerebrovascular Disorders / Q000453:epidemiology* / Q000517:prevention & control*; D015897:Comorbidity; D050171:Dyslipidemias / Q000453:epidemiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data*; D010353:Patient Education as Topic; D012307:Risk Factors; D040242:Risk Reduction Behavior; D017678:Sex Distribution
chemical_list: D000959:Antihypertensive Agents